We serve DL-10-Camphorsulfonic Acid CAS:5872-08-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
| Items of Analysis | Standard of Analysis | Test Results |
| Appearance | White to off-white crystalline powder | Conform |
| Loss on drying | ≤1.0% | 0.55% |
| Specific Rotation | 0°±1° | +21.5° |
| Melting point | 192℃-202℃ | 197.5-198.6℃ |
| Purity | ≥99% | 99.66% |
| Conclusion | Conforms to Factory Standard | |
Contact us for information like DL-10-Camphorsulfonic Acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(7,7-Dimethyl-2-oxobicyclo[2.2.1]-heptan-1-yl)methanesulfonic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,DL-10-Camphorsulfonic Acid Use and application,(7,7-Dimethyl-2-oxobicyclo[2.2.1]-heptan-1-yl)methanesulfonic acid technical grade,usp/ep/jp grade.
Related News: The technology supports breakthroughs in medical research and is widely used by major global pharmaceutical companies to advance drug discovery & development and provide data to support regulatory submissions. 4-bromo-N-(α-methoxyphenacyl)aniline manufacturer “We are very worried,” Chuang Shuk-kwan, a health official, said at a news conference on Sunday. “Everyone should prepare mentally for the possibility that the disease is spreading within the community.”3-hydroxy-1-(3-hydroxy-6-(((2-hydroxy-24,34,43,53-pentaoxol-3-yl)(oxo)-4-oxidaneyl)oxy)-13,24,34,43,53,64-hexaoxin-2-yl)-14,33-tetraoxidan-1-one supplier The Shanghai Institute of Materia Medica is under the Chinese Academy of Sciences (CAS), a top government think tank. The Wuhan Institute of Virology is also administered by the CAS and is among the country’s most advanced virus research laboratories.(3R,5R,10S)-10-(4-fluorophenyl)-3-methoxy-3-(2-methoxy-5-(trifluoromethyl)phenyl)-9-(2-(trifluoromethyl)benzyl)-1,6-dioxa-9-azaspiro[4.5]decane vendor This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care. This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.
